Literature DB >> 7047001

Serum lipids, postheparin plasma lipase activities and glucose tolerance in patients with prolactinoma.

R Pelkonen, E A Nikkilä, B Grahne.   

Abstract

UNLABELLED: Serum total cholesterol and triglyceride levels were determined in forty-seven women with prolactinoma and in eighty-four age- and weight-matched control women. Oral glucose tolerance tests (OGTT) were performed and postheparin plasma lipoprotein lipase (LPL) and hepatic lipase (HL) activities were determined in twelve patients before and after transsphenoidal removal of the prolactinoma. The mean levels of serum cholesterol and triglyceride were significantly higher in patients than in controls. The 90% cut-off line of controls for serum cholesterol was exceeded by 36% and that for serum triglyceride by 23% of the patients. The triglyceride levels were raised only in patients with GH-deficiency whereas patients with normal GH secretion had normal triglyceride. Plasma LPL activity was significantly reduced whereas plasma HL activity was in the upper range of normal. After the removal of prolactinoma the serum prolactin levels decreased in all patients and seven started to menstruate. The oral glucose tolerance was improved and the plasma insulin response decreased. Serum lipid levels and the lipase activities, however, did not change.
CONCLUSION: prolactinoma is associated with metabolic abnormalities characterized by hyperlipidaemia, low plasma LPL activity and insulin resistance.

Entities:  

Mesh:

Substances:

Year:  1982        PMID: 7047001     DOI: 10.1111/j.1365-2265.1982.tb00731.x

Source DB:  PubMed          Journal:  Clin Endocrinol (Oxf)        ISSN: 0300-0664            Impact factor:   3.478


  13 in total

1.  Insulin sensitivity and lipid profile in prolactinoma patients before and after normalization of prolactin by dopamine agonist therapy.

Authors:  Katarina Berinder; Thomas Nyström; Charlotte Höybye; Kerstin Hall; Anna-Lena Hulting
Journal:  Pituitary       Date:  2011-09       Impact factor: 4.107

2.  Effect of cabergoline on insulin sensitivity, inflammation, and carotid intima media thickness in patients with prolactinoma.

Authors:  Serap Soytac Inancli; Alper Usluogullari; Yusuf Ustu; Sedat Caner; Abbas Ali Tam; Reyhan Ersoy; Bekir Cakir
Journal:  Endocrine       Date:  2012-12-12       Impact factor: 3.633

Review 3.  Clinical Management of Hypertriglyceridemia in the Prevention of Cardiovascular Disease and Pancreatitis.

Authors:  Patricia Hernandez; Neena Passi; Taher Modarressi; Vivek Kulkarni; Meshal Soni; Fran Burke; Archna Bajaj; Daniel Soffer
Journal:  Curr Atheroscler Rep       Date:  2021-09-13       Impact factor: 5.113

4.  Chronic hyperprolactinemia and plasma lipids in women.

Authors:  H M Heshmati; G Turpin; J L de Gennes
Journal:  Klin Wochenschr       Date:  1987-06-01

5.  Evaluation of insulin sensitivity in hyperprolactinemic subjects by euglycemic hyperinsulinemic clamp technique.

Authors:  Alpaslan Tuzcu; Serkan Yalaki; Senay Arikan; Deniz Gokalp; Mithat Bahcec; Sadiye Tuzcu
Journal:  Pituitary       Date:  2009-05-01       Impact factor: 4.107

Review 6.  The effects of hyperprolactinemia on bone and fat.

Authors:  Amal Shibli-Rahhal; Janet Schlechte
Journal:  Pituitary       Date:  2009       Impact factor: 4.107

7.  Prolactin-secreting pituitary adenomas.

Authors:  M C Martin; E D Schriock; R B Jaffe
Journal:  West J Med       Date:  1983-11

8.  Microcirculation and atherothrombotic parameters in prolactinoma patients: a pilot study.

Authors:  Anne Q Reuwer; Brigitte M Sondermeijer; Suzanne Battjes; Rogier van Zijderveld; Danka J F Stuijver; Peter H Bisschop; Marcel Th B Twickler; Joost C M Meijers; Reinier O Schlingemann; Erik S Stroes
Journal:  Pituitary       Date:  2012-12       Impact factor: 4.107

9.  Metabolic abnormalities in patients with prolactinoma: response to treatment with cabergoline.

Authors:  Nazir A Pala; Bashir A Laway; Raiz A Misgar; Rayees A Dar
Journal:  Diabetol Metab Syndr       Date:  2015-11-14       Impact factor: 3.320

10.  Successful Improvement of Metabolic Disorders, Including Osteopenia, by a Dopamine Agonist in a Male Patient with Macro-Prolactinoma.

Authors:  Ayumu Takeno; Masahiro Yamamoto; Kyoko Okazaki; Toru Yamaguchi; Toshitsugu Sugimoto
Journal:  Am J Case Rep       Date:  2016-03-13
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.